Johnson & Johnson Buys Firefly Bio for $1 Billion to Enter KRAS Cancer Drug Race
Updated
Updated · STAT · Jun 8
Johnson & Johnson Buys Firefly Bio for $1 Billion to Enter KRAS Cancer Drug Race
3 articles · Updated · STAT · Jun 8
Summary
$1 billion will buy Johnson & Johnson a foothold in KRAS-targeted cancer drugs through startup Firefly Bio, marking a push into one of oncology's hottest new areas.
The move follows Revolution Medicines data less than two months ago showing a KRAS drug nearly doubled survival in metastatic pancreatic cancer, helping validate a target long seen as difficult to drug.
Firefly brings a degrader antibody conjugate platform aimed at KRAS-driven and other solid tumors, giving J&J another route to develop treatments for hard-to-treat cancers.
KRAS mutations appear in about 30% of tumors, and recent clinical progress has intensified competition among drugmakers to crack a protein once likened to a 'greasy ball.'
After a rival's fatal trial, is Johnson & Johnson's $1B bet on a similar high-risk cancer platform a wise move?
Why did J&J spend $1B on a new KRAS platform while its own similar drug is already in Phase 3 trials?
Johnson & Johnson’s $1 Billion Acquisition of Firefly Bio: A Bold Leap Toward KRAS-Targeted Cancer Therapies
Overview
Johnson & Johnson (J&J) has announced a $1 billion cash acquisition of Firefly Bio, Inc., expected to close later in 2026. This move is a major step for J&J to expand its oncology pipeline and strengthen its focus on targeted cancer medicines. Central to the deal is Firefly Bio’s proprietary Firelink platform, which uses antibodies to deliver protein-degrading drugs directly into cancer cells. J&J believes this technology could attack tumors while sparing healthy tissue, offering a crucial advantage in treating challenging cancers, especially those with specific genetic mutations.